Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2014-09-18 Board/Management Inform…
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 16, 2014, reporting the appointment of Mark W. Schwartz, Ph.D. as President, CEO, and director of Galena Biopharma, Inc. It details his employment agreement and appointment to the board. The key section is Item 5.02, which relates to departure and appointment of directors and officers. There are no financial statements or earnings data, nor is this a report of voting results or a proxy statement. The document is clearly an announcement of changes in senior management and board composition. Therefore, it fits the category of Board/Management Information (MANG). The document length (5701 characters) supports it being a full announcement rather than a brief notice or certification. Confidence is high given the explicit content and form type.
2014-09-18 English
PRIMARY DOCUMENT
Director's Dealing
2014-09-18 English
8-K/A
Regulatory Filings Classification · 100% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It corrects a typographical error regarding the date of an amendment to an employment agreement. There is no new financial data or detailed report content; it is a regulatory filing to update or correct previously submitted information. The document length is short (2419 characters), and it serves as an official correction notice rather than a full report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS).
2014-08-26 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated August 20, 2014, for Galena Biopharma, Inc. The key content is the announcement of the departure of the former CEO and the appointment of a new CEO, including details about the employment agreement and stock options. There is no financial data or report content, only management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3251 characters, which is short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2014-08-22 English
10-Q
Interim / Quarterly Report Q2 2014
2014-08-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2014, reporting the company's financial results for the second quarter ended June 30, 2014. It includes a press release attached as Exhibit 99.1 announcing these results. The text explicitly states this is a current report pursuant to the Securities Exchange Act of 1934 and is not the full quarterly report itself but a press release announcing the results. The document length is 2946 characters, which is relatively short and consistent with an earnings release rather than a full interim report. The key phrase 'issued a press release announcing our financial results' and the attachment of the press release indicate this is an Earnings Release (ER) filing rather than a full Interim/Quarterly Report (IR). Therefore, the correct classification is Earnings Release (ER).
2014-08-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.